The Role of Antimicrobial Foam Dressing in Prevention of Cesarean Section Wound Complications

N/A

Waitlist Available

Led By Jean Goodman, MD

Research Sponsored by Loyola University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks postoperative

Awards & highlights

No Placebo-Only Group

Summary

Post-cesarean section wound infections are responsible for longer hospital stays, readmissions, and ultimately, increased costs to the healthcare system. Silver-containing dressings may prevent wound infections. The purpose of the current study is to determine if the use of a silver-impregnated dressing decreases the occurence of wound infection following cesarean delivery.

Eligible Conditions

Cesarean Section Wound Dehiscence

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks postoperative

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks postoperative

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks postoperative for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants With Wound Disruption and/or Infection

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Silver-impregnated antimicrobial dressingExperimental Treatment1 Intervention

All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Silver-impregnated antimicrobial dressing

2017

N/A

~380

Do I qualify?Apply below to find out